MedPath

Ketoconazole

Generic Name
Ketoconazole
Brand Names
Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
Drug Type
Small Molecule
Chemical Formula
C26H28Cl2N4O4
CAS Number
65277-42-1
Unique Ingredient Identifier
R9400W927I
Background

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, miconazole and clotrimazole, due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis. These effects combined with waning efficacy led to its eventual replacement by triazole agents, fluconazole, itraconazole, voriconazole, and posaconazole. Ketoconazole and its predecessor clotrimazole continue to be used in topical formulations.

Indication

Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.

Associated Conditions
Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection

Effect of Ketoconazole on Biliary Excretion of AZD0837

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2008-12-22
Last Posted Date
2010-12-03
Lead Sponsor
AstraZeneca
Target Recruit Count
20
Registration Number
NCT00812344
Locations
🇸🇪

Research Site, Uppsala, Sweden

To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil

Phase 1
Completed
Conditions
Erectile Dysfunction
Interventions
First Posted Date
2008-10-09
Last Posted Date
2009-12-02
Lead Sponsor
VIVUS LLC
Target Recruit Count
44
Registration Number
NCT00770042
Locations
🇺🇸

Research Site, Lincoln, Nebraska, United States

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

Phase 1
Completed
Conditions
HCV Infection
Interventions
First Posted Date
2008-10-08
Last Posted Date
2010-10-13
Lead Sponsor
Abbott
Target Recruit Count
45
Registration Number
NCT00768690
Locations
🇺🇸

Site Reference ID/Investigator# 12701, Waukegan, Illinois, United States

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
First Posted Date
2008-07-02
Last Posted Date
2014-01-17
Lead Sponsor
University of Chicago
Target Recruit Count
57
Registration Number
NCT00708591
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

An Interaction Study of Ketoconazole/Verapamil Versus AZD1305

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2008-07-01
Last Posted Date
2010-12-03
Lead Sponsor
AstraZeneca
Target Recruit Count
27
Registration Number
NCT00707551
Locations
🇩🇪

Research Site, Berlin, Germany

STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2%

Phase 4
Completed
Conditions
Dermatitis, Seborrheic
Interventions
First Posted Date
2008-06-24
Last Posted Date
2017-01-30
Lead Sponsor
Stiefel, a GSK Company
Target Recruit Count
498
Registration Number
NCT00703846

Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel

Phase 2
Completed
Conditions
Solid Tumors
Interventions
First Posted Date
2008-06-13
Last Posted Date
2013-12-10
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
10
Registration Number
NCT00697437
Locations
🇸🇬

National University Hospital, Singapore, Singapore

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

Phase 2
Terminated
Conditions
Burns
Interventions
Procedure: Stable Isotope Infusion Study
Procedure: Collection of blood and tissues
Drug: Placebo
Behavioral: Exercise--Hospital supervised intensive exercise program
Behavioral: Home exercise program
First Posted Date
2008-05-12
Last Posted Date
2019-11-29
Lead Sponsor
The University of Texas Medical Branch, Galveston
Target Recruit Count
1126
Registration Number
NCT00675714
Locations
🇺🇸

University of Texas Medical Branch, Galveston, Texas, United States

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

Phase 2
Completed
Conditions
Hormonal Cycling
Prostate
Cancer
Interventions
First Posted Date
2008-01-07
Last Posted Date
2016-03-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
36
Registration Number
NCT00586898
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

Not Applicable
Withdrawn
Conditions
Prostate Cancer
First Posted Date
2007-11-16
Last Posted Date
2013-02-01
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT00559481
© Copyright 2025. All Rights Reserved by MedPath